This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are
presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.
"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.
Num | microRNA | Gene | miRNA log2FC | miRNA pvalue | Gene log2FC | Gene pvalue | Interaction | Correlation beta | Correlation P-value | PMID | Reported in cancer studies |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | hsa-miR-93-3p | ABHD15 | -0.4 | 0.00131 | 1.3 | 0 | MirTarget | -0.19 | 0.01073 | NA | |
2 | hsa-miR-93-3p | ABHD2 | -0.4 | 0.00131 | 1.2 | 0 | mirMAP | -0.29 | 0 | NA | |
3 | hsa-miR-93-3p | ACSL1 | -0.4 | 0.00131 | 2.33 | 0 | miRNAWalker2 validate | -0.44 | 1.0E-5 | NA | |
4 | hsa-miR-93-3p | ADAMTSL2 | -0.4 | 0.00131 | 2.68 | 0 | mirMAP | -0.38 | 0.00556 | NA | |
5 | hsa-miR-145-5p | ADM2 | 1.48 | 0 | -1.72 | 0 | mirMAP | -0.17 | 0.01295 | NA | |
6 | hsa-miR-93-3p | AIF1L | -0.4 | 0.00131 | -0.76 | 0.0005 | MirTarget | -0.2 | 0.01823 | NA | |
7 | hsa-miR-93-3p | AKAP11 | -0.4 | 0.00131 | 0.7 | 0 | MirTarget | -0.2 | 0 | NA | |
8 | hsa-miR-145-5p | ALDH3A1 | 1.48 | 0 | -1.6 | 0.0148 | miRNAWalker2 validate | -0.42 | 0.01262 | NA | |
9 | hsa-miR-145-5p | ANGPT2 | 1.48 | 0 | -1.15 | 0 | MirTarget; miRNATAP | -0.2 | 6.0E-5 | 24384875; 27570490 | miR 145 functions as tumor suppressor and targets two oncogenes ANGPT2 and NEDD9 in renal cell carcinoma; We further validated those miR-145 targets two oncogenes ANGPT2 and NEDD9 in RCC;MiR 145 functions as a tumor suppressor via regulating angiopoietin 2 in pancreatic cancer cells; The direct action of miR-145 on Ang-2 was predicted by TargetScan and confirmed by luciferase report assay; The expression level of miR-145 was significantly lower and the expression levels of Ang-2 mRNA and protein was significantly higher in the more aggressive pancreatic cancer cells MiaPaCa-2 and Panc-1 when compared to that in BxPC3 cells; Overexpression of miR-145 in the BxPC3 MiaPaCa-2 and Panc-1 cells suppressed the cell invasion and colony formation ability and the expression level of Ang-2 protein in MiaPaCa-2 and Panc-1 cells was also suppressed after pre-miR-145 transfection; Intratumoral delivery of miR-145 inhibited the growth of pancreatic cancer xenografts and angiogenesis in vivo and also suppressed the expression level of angiopoietin-2 protein; MiR-145 functions as a tumor suppressor in pancreatic cancer cells by targeting Ang-2 for translation repression and thus suppresses pancreatic cancer cell invasion and growth which suggests that restoring of miR-145 may be a potential therapeutic target for pancreatic cancer |
10 | hsa-miR-93-3p | ANKFY1 | -0.4 | 0.00131 | 0.58 | 0 | mirMAP | -0.19 | 0 | NA | |
11 | hsa-miR-145-5p | ANKRD52 | 1.48 | 0 | -1.46 | 0 | miRNATAP | -0.2 | 0 | NA | |
12 | hsa-miR-93-3p | AOAH | -0.4 | 0.00131 | 1.16 | 0 | MirTarget | -0.24 | 0.01099 | NA | |
13 | hsa-miR-93-3p | AP3S2 | -0.4 | 0.00131 | 0.33 | 4.0E-5 | mirMAP | -0.14 | 1.0E-5 | NA | |
14 | hsa-miR-145-5p | APH1A | 1.48 | 0 | -0.33 | 1.0E-5 | miRNAWalker2 validate | -0.1 | 0 | NA | |
15 | hsa-miR-93-3p | ARID4A | -0.4 | 0.00131 | 0.9 | 0 | MirTarget | -0.12 | 0.01309 | NA | |
16 | hsa-miR-93-3p | ARIH1 | -0.4 | 0.00131 | 0.13 | 0.06993 | MirTarget | -0.13 | 0 | NA | |
17 | hsa-miR-93-3p | ARSD | -0.4 | 0.00131 | 1.16 | 0 | mirMAP | -0.26 | 2.0E-5 | NA | |
18 | hsa-miR-93-3p | ASB7 | -0.4 | 0.00131 | 0.2 | 0.00927 | miRNATAP | -0.11 | 0.00025 | NA | |
19 | hsa-miR-425-3p | ATMIN | 0.16 | 0.22372 | 0.37 | 0 | miRNAWalker2 validate | -0.13 | 0 | NA | |
20 | hsa-miR-93-3p | ATRN | -0.4 | 0.00131 | -0.12 | 0.34173 | MirTarget | -0.1 | 0.03433 | NA | |
21 | hsa-miR-145-5p | ATXN7L3 | 1.48 | 0 | -0.7 | 0 | miRNATAP | -0.12 | 0 | NA | |
22 | hsa-miR-93-3p | BMPR2 | -0.4 | 0.00131 | 0.74 | 0 | miRNAWalker2 validate | -0.19 | 0 | NA | |
23 | hsa-miR-93-3p | BNC2 | -0.4 | 0.00131 | 0.39 | 0.08973 | miRNATAP | -0.33 | 0.00021 | NA | |
24 | hsa-miR-145-5p | BNIP3 | 1.48 | 0 | 0.57 | 1.0E-5 | miRNAWalker2 validate; miRTarBase | -0.1 | 0.00184 | 20332243 | Artificial overexpression of miR145 by using adenoviral vectors in prostate cancer PC-3 and DU145 cells significantly downregulated BNIP3 together with the upregulation of AIF reduced cell growth and increased cell death; Analysis of prostate cancer n = 134 and benign prostate n = 83 tissue sample showed significantly decreased miR145 and increased BNIP3 expression in prostate cancer P < 0.001 particularly in those with tumor progression and both molecular changes were associated with unfavorable outcome |
25 | hsa-miR-145-5p | BRWD3 | 1.48 | 0 | -0.1 | 0.5367 | miRNATAP | -0.11 | 0.00504 | NA | |
26 | hsa-miR-145-5p | BSN | 1.48 | 0 | -0.94 | 2.0E-5 | miRNATAP | -0.27 | 0 | NA | |
27 | hsa-miR-93-3p | C17orf51 | -0.4 | 0.00131 | 0.67 | 0.00164 | mirMAP | -0.22 | 0.00908 | NA | |
28 | hsa-miR-93-3p | CACNA1C | -0.4 | 0.00131 | -0.95 | 1.0E-5 | mirMAP | -0.35 | 4.0E-5 | NA | |
29 | hsa-miR-93-3p | CACNB2 | -0.4 | 0.00131 | 0.29 | 0.15115 | MirTarget; miRNATAP | -0.19 | 0.01446 | NA | |
30 | hsa-miR-93-3p | CAMK1D | -0.4 | 0.00131 | 0.4 | 0.12354 | mirMAP | -0.45 | 1.0E-5 | NA | |
31 | hsa-miR-93-3p | CBR1 | -0.4 | 0.00131 | 0.13 | 0.46223 | miRNAWalker2 validate | -0.29 | 2.0E-5 | NA | |
32 | hsa-miR-93-3p | CCDC113 | -0.4 | 0.00131 | 0.25 | 0.30312 | mirMAP | -0.27 | 0.00318 | NA | |
33 | hsa-miR-93-3p | CCDC69 | -0.4 | 0.00131 | 0.78 | 0 | mirMAP | -0.24 | 0.00019 | NA | |
34 | hsa-miR-145-5p | CDK4 | 1.48 | 0 | -0.67 | 0 | miRNAWalker2 validate; miRTarBase | -0.15 | 0 | 21092188 | Furthermore we found that CDK4 was regulated by miR-145 in cell cycle control |
35 | hsa-miR-145-5p | CEP78 | 1.48 | 0 | -0.35 | 0.00104 | mirMAP | -0.11 | 8.0E-5 | NA | |
36 | hsa-miR-93-3p | CGNL1 | -0.4 | 0.00131 | 0.69 | 0.00039 | mirMAP | -0.21 | 0.00603 | NA | |
37 | hsa-miR-93-3p | CLN8 | -0.4 | 0.00131 | 0.9 | 0 | mirMAP | -0.12 | 0.02383 | NA | |
38 | hsa-miR-93-3p | COL4A3BP | -0.4 | 0.00131 | 0.61 | 0 | MirTarget | -0.17 | 0 | NA | |
39 | hsa-miR-145-5p | COMMD5 | 1.48 | 0 | -0.84 | 0 | MirTarget | -0.16 | 0 | NA | |
40 | hsa-miR-145-5p | COMMD9 | 1.48 | 0 | -0.25 | 0.00305 | MirTarget | -0.1 | 0 | NA | |
41 | hsa-miR-93-3p | CPEB2 | -0.4 | 0.00131 | 0.78 | 0 | miRNATAP | -0.21 | 0.00017 | NA | |
42 | hsa-miR-93-3p | CPNE8 | -0.4 | 0.00131 | 0.76 | 0 | MirTarget; miRNATAP | -0.21 | 8.0E-5 | NA | |
43 | hsa-miR-93-3p | CPS1 | -0.4 | 0.00131 | 2.85 | 0 | MirTarget | -1.14 | 0 | NA | |
44 | hsa-miR-93-3p | CREB3L3 | -0.4 | 0.00131 | 1.3 | 1.0E-5 | mirMAP | -0.3 | 0.00933 | NA | |
45 | hsa-miR-93-3p | CUX1 | -0.4 | 0.00131 | 0.19 | 0.03981 | mirMAP | -0.14 | 7.0E-5 | NA | |
46 | hsa-miR-93-3p | CXorf23 | -0.4 | 0.00131 | -0.43 | 1.0E-5 | miRNATAP | -0.13 | 0.00046 | NA | |
47 | hsa-miR-93-3p | DCAF8 | -0.4 | 0.00131 | 0.03 | 0.75166 | MirTarget | -0.15 | 0 | NA | |
48 | hsa-miR-93-3p | DDI2 | -0.4 | 0.00131 | 1.53 | 0 | MirTarget | -0.3 | 0.01958 | NA | |
49 | hsa-miR-93-3p | DLG2 | -0.4 | 0.00131 | 1.95 | 0 | MirTarget; miRNATAP | -0.55 | 0 | NA | |
50 | hsa-miR-145-5p | DNAJB11 | 1.48 | 0 | -0.85 | 0 | miRNATAP | -0.14 | 0 | NA | |
51 | hsa-miR-93-3p | DNAJC27 | -0.4 | 0.00131 | 0.35 | 0.00026 | MirTarget | -0.15 | 8.0E-5 | NA | |
52 | hsa-miR-145-5p | DNMT3B | 1.48 | 0 | -1.62 | 0 | MirTarget | -0.23 | 0 | 24071015; 25749421 | In univariate analysis the combination of DNMT3B overexpression and miR-145 or miR-143 down-regulation was more powerful in predicting shorter survival P < .05 than use of the biomarkers individually P > .05; DNMT3B might be a potential target of miR-145 and miR-143 in ECs; Furthermore the combined miR-145 or miR-143 and DNMT3B status may have a prognostic impact on ECs;It was found that miR-145 upregulates while DNMT3b downregulates in PC3 cells; Responses of the miR-145 and DNMT3b to irradiation are a negative correlation; We also found that either overexpression of miR-145 or knockdown of DNMT3b sensitized prostate cancer cells to X-ray radiation |
53 | hsa-miR-425-3p | DUSP1 | 0.16 | 0.22372 | 2.02 | 0 | MirTarget | -0.33 | 7.0E-5 | NA | |
54 | hsa-miR-145-5p | EFNA3 | 1.48 | 0 | -1.75 | 0 | miRNATAP | -0.28 | 0 | NA | |
55 | hsa-miR-93-3p | EML1 | -0.4 | 0.00131 | 0.63 | 0.00019 | MirTarget | -0.25 | 0.0002 | NA | |
56 | hsa-miR-93-3p | EMP2 | -0.4 | 0.00131 | 0.3 | 0.02441 | mirMAP | -0.16 | 0.0016 | NA | |
57 | hsa-miR-93-3p | EPHA3 | -0.4 | 0.00131 | 1.76 | 0 | MirTarget | -0.57 | 0 | NA | |
58 | hsa-miR-145-5p | ERF | 1.48 | 0 | -0.14 | 0.14928 | MirTarget; miRNATAP | -0.11 | 0 | NA | |
59 | hsa-miR-145-5p | ESCO2 | 1.48 | 0 | -1.8 | 0 | MirTarget | -0.35 | 0 | NA | |
60 | hsa-miR-145-5p | FAM104A | 1.48 | 0 | -0.38 | 0 | MirTarget | -0.14 | 0 | NA | |
61 | hsa-miR-145-5p | FAM134A | 1.48 | 0 | -0.31 | 1.0E-5 | MirTarget | -0.11 | 0 | NA | |
62 | hsa-miR-145-5p | FAM49B | 1.48 | 0 | -0.71 | 0 | MirTarget | -0.11 | 0.0002 | NA | |
63 | hsa-miR-93-3p | FETUB | -0.4 | 0.00131 | 2.8 | 0 | MirTarget | -0.49 | 0.00603 | NA | |
64 | hsa-miR-93-3p | FGF2 | -0.4 | 0.00131 | 1.09 | 0.00032 | mirMAP | -0.44 | 0.00021 | NA | |
65 | hsa-miR-93-3p | FKBP5 | -0.4 | 0.00131 | 0.23 | 0.1942 | miRNAWalker2 validate | -0.22 | 0.00132 | NA | |
66 | hsa-miR-145-5p | FLRT1 | 1.48 | 0 | -1.05 | 0 | MirTarget | -0.17 | 0.0023 | NA | |
67 | hsa-miR-93-3p | FOSL2 | -0.4 | 0.00131 | 0.44 | 0.00385 | mirMAP | -0.17 | 0.00339 | NA | |
68 | hsa-miR-93-3p | FTO | -0.4 | 0.00131 | 0.23 | 0.00923 | mirMAP | -0.18 | 0 | NA | |
69 | hsa-miR-93-3p | FYN | -0.4 | 0.00131 | 1.06 | 0 | miRNAWalker2 validate | -0.29 | 0 | NA | |
70 | hsa-miR-93-3p | GAB3 | -0.4 | 0.00131 | 0.34 | 0.01974 | MirTarget | -0.21 | 0.00015 | NA | |
71 | hsa-miR-425-3p | GABPB2 | 0.16 | 0.22372 | -0.81 | 0 | miRNAWalker2 validate | -0.12 | 0.02062 | NA | |
72 | hsa-miR-145-5p | GATC | 1.48 | 0 | -0.06 | 0.6266 | MirTarget | -0.12 | 0.00027 | NA | |
73 | hsa-miR-93-3p | GCAT | -0.4 | 0.00131 | 0.89 | 2.0E-5 | miRNAWalker2 validate | -0.19 | 0.02432 | NA | |
74 | hsa-miR-93-3p | GDF2 | -0.4 | 0.00131 | 8.7 | 0 | MirTarget | -0.78 | 0.00055 | NA | |
75 | hsa-miR-93-3p | GFOD1 | -0.4 | 0.00131 | 0.74 | 0 | mirMAP | -0.31 | 0 | NA | |
76 | hsa-miR-145-5p | GGT7 | 1.48 | 0 | -0.02 | 0.84677 | MirTarget; miRNATAP | -0.11 | 0.00019 | NA | |
77 | hsa-miR-93-3p | GIMAP1 | -0.4 | 0.00131 | 0.32 | 0.02436 | mirMAP | -0.3 | 0 | NA | |
78 | hsa-miR-93-3p | GIPC3 | -0.4 | 0.00131 | -0.21 | 0.11552 | mirMAP | -0.27 | 0 | NA | |
79 | hsa-miR-93-3p | GLUD1 | -0.4 | 0.00131 | 1.37 | 0 | miRNAWalker2 validate | -0.17 | 0.01094 | NA | |
80 | hsa-miR-93-3p | GNAO1 | -0.4 | 0.00131 | 3.67 | 0 | mirMAP | -0.59 | 0.00022 | NA | |
81 | hsa-miR-93-3p | GOT2 | -0.4 | 0.00131 | 1.22 | 0 | miRNAWalker2 validate | -0.35 | 0 | NA | |
82 | hsa-miR-93-3p | GPD1 | -0.4 | 0.00131 | 2.61 | 0 | miRNATAP | -0.5 | 0.00014 | NA | |
83 | hsa-miR-145-5p | GPD2 | 1.48 | 0 | -0.4 | 0.00037 | miRNATAP | -0.1 | 0.00039 | NA | |
84 | hsa-miR-145-5p | H2AFX | 1.48 | 0 | -1.27 | 0 | MirTarget; miRNATAP | -0.25 | 0 | NA | |
85 | hsa-miR-93-3p | H6PD | -0.4 | 0.00131 | 0.16 | 0.26926 | mirMAP | -0.13 | 0.0241 | NA | |
86 | hsa-miR-93-3p | HACL1 | -0.4 | 0.00131 | 0.46 | 0.00012 | miRNAWalker2 validate | -0.13 | 0.00694 | NA | |
87 | hsa-miR-93-3p | HDX | -0.4 | 0.00131 | 0.73 | 0.00194 | MirTarget | -0.27 | 0.00306 | NA | |
88 | hsa-miR-93-3p | HEG1 | -0.4 | 0.00131 | -0.18 | 0.20986 | mirMAP | -0.16 | 0.00273 | NA | |
89 | hsa-miR-93-3p | HHIPL1 | -0.4 | 0.00131 | 0.66 | 0.00092 | mirMAP | -0.16 | 0.04048 | NA | |
90 | hsa-miR-145-5p | HIC2 | 1.48 | 0 | -0.94 | 0 | miRNATAP | -0.2 | 0 | NA | |
91 | hsa-miR-145-5p | HLTF | 1.48 | 0 | -0.44 | 0.00015 | miRNAWalker2 validate | -0.13 | 1.0E-5 | 25666710 | We show that miR-145 targets the DNA damage repair-associated gene Helicase-like transcription factor HLTF which is involved in radio-resistance |
92 | hsa-miR-93-3p | HSPG2 | -0.4 | 0.00131 | -0.55 | 0.00034 | mirMAP | -0.14 | 0.01567 | NA | |
93 | hsa-miR-93-3p | IKZF1 | -0.4 | 0.00131 | 0.97 | 0 | mirMAP | -0.22 | 0.00379 | NA | |
94 | hsa-miR-93-3p | IKZF2 | -0.4 | 0.00131 | 0.83 | 1.0E-5 | MirTarget; miRNATAP | -0.18 | 0.01897 | NA | |
95 | hsa-miR-93-3p | IL6ST | -0.4 | 0.00131 | 1.92 | 0 | MirTarget | -0.54 | 5.0E-5 | NA | |
96 | hsa-miR-145-5p | IRS1 | 1.48 | 0 | 0.22 | 0.13754 | miRNAWalker2 validate; miRTarBase; MirTarget | -0.15 | 0.00011 | 22431718; 24690171; 24762580 | Luciferase reporter assay further verified direct target association of miR-145 to specific sites of the IRS1 and IRS2 3'-untranslated regions;MicroRNA 145 suppresses hepatocellular carcinoma by targeting IRS1 and its downstream Akt signaling; We verified IRS1 as a direct target of miR-145 using Western blotting and luciferase reporter assay; Further the restoration of miR-145 in HCC cell lines suppressed cancer cell growth owing to down-regulated IRS1 expression and its downstream Akt/FOXO1 signaling; Our results demonstrated that miR-145 could inhibit HCC through targeting IRS1 and its downstream signaling implicating the loss of miR-145 regulation may be a potential molecular mechanism causing aberrant oncogenic signaling in HCC;IRS-1 was identified as a potential target of miR-145 by dual luciferase reporter assay; Knocking down of IRS-1 had similar effect as overexpression of miR-145 miR-145 might act as a tumor suppressor in uveal melanoma and downregulation of the target IRS-1 might be a potential mechanism |
97 | hsa-miR-93-3p | ITPRIP | -0.4 | 0.00131 | 0.93 | 0 | miRNAWalker2 validate | -0.4 | 0 | NA | |
98 | hsa-miR-93-3p | ITSN1 | -0.4 | 0.00131 | 0.75 | 0 | mirMAP | -0.13 | 0.00255 | NA | |
99 | hsa-miR-93-3p | KCTD15 | -0.4 | 0.00131 | 0.04 | 0.83421 | mirMAP | -0.16 | 0.04144 | NA | |
100 | hsa-miR-93-3p | KIAA1644 | -0.4 | 0.00131 | 1.81 | 0 | mirMAP | -0.51 | 2.0E-5 | NA | |
101 | hsa-miR-93-3p | KIAA1671 | -0.4 | 0.00131 | 0.84 | 0 | miRNAWalker2 validate | -0.29 | 0 | NA | |
102 | hsa-miR-93-3p | KIRREL | -0.4 | 0.00131 | 0.92 | 0.00842 | mirMAP | -0.35 | 0.01013 | NA | |
103 | hsa-miR-93-3p | KLF12 | -0.4 | 0.00131 | 0.86 | 0 | MirTarget; mirMAP | -0.19 | 0.00134 | NA | |
104 | hsa-miR-93-3p | KLF9 | -0.4 | 0.00131 | 1.36 | 0 | miRNATAP | -0.53 | 0 | NA | |
105 | hsa-miR-425-3p | KLHL15 | 0.16 | 0.22372 | 1.44 | 0 | miRNAWalker2 validate | -0.11 | 0.03077 | NA | |
106 | hsa-miR-93-3p | KLHL2 | -0.4 | 0.00131 | 1.17 | 0 | miRNATAP | -0.29 | 0 | NA | |
107 | hsa-miR-93-3p | KLHL30 | -0.4 | 0.00131 | -0.9 | 0.00135 | mirMAP | -0.25 | 0.02301 | NA | |
108 | hsa-miR-93-3p | KLRD1 | -0.4 | 0.00131 | 1.83 | 0 | MirTarget | -0.39 | 4.0E-5 | NA | |
109 | hsa-miR-93-3p | LAX1 | -0.4 | 0.00131 | 0.86 | 0.00023 | MirTarget | -0.19 | 0.04355 | NA | |
110 | hsa-miR-93-3p | LCOR | -0.4 | 0.00131 | 0.83 | 0.00038 | miRNATAP | -0.27 | 0.00308 | NA | |
111 | hsa-miR-93-3p | LRBA | -0.4 | 0.00131 | 0.51 | 0 | miRNAWalker2 validate | -0.11 | 0.00994 | NA | |
112 | hsa-miR-93-3p | LRRC27 | -0.4 | 0.00131 | -0.18 | 0.09935 | mirMAP | -0.11 | 0.01055 | NA | |
113 | hsa-miR-93-3p | LRRC34 | -0.4 | 0.00131 | 0.13 | 0.22881 | miRNAWalker2 validate | -0.1 | 0.01373 | NA | |
114 | hsa-miR-93-3p | LYRM7 | -0.4 | 0.00131 | 0.29 | 0.00075 | mirMAP | -0.1 | 0.00232 | NA | |
115 | hsa-miR-145-5p | MAGOHB | 1.48 | 0 | -0.4 | 1.0E-5 | MirTarget | -0.11 | 0 | NA | |
116 | hsa-miR-93-3p | MAN1C1 | -0.4 | 0.00131 | 2.43 | 0 | MirTarget | -0.54 | 0 | NA | |
117 | hsa-miR-145-5p | MAP2K6 | 1.48 | 0 | -0.14 | 0.55112 | miRNAWalker2 validate | -0.15 | 0.01692 | NA | |
118 | hsa-miR-93-3p | MAP9 | -0.4 | 0.00131 | 1.38 | 0 | MirTarget | -0.31 | 0.004 | NA | |
119 | hsa-miR-145-5p | MBNL3 | 1.48 | 0 | 0.6 | 0.01424 | miRNATAP | -0.19 | 0.00192 | NA | |
120 | hsa-miR-425-3p | MDH2 | 0.16 | 0.22372 | -0.07 | 0.50754 | miRNAWalker2 validate | -0.13 | 0.00167 | NA | |
121 | hsa-miR-93-3p | MID2 | -0.4 | 0.00131 | -0.02 | 0.91611 | MirTarget | -0.33 | 0 | NA | |
122 | hsa-miR-93-3p | MKL2 | -0.4 | 0.00131 | -0.02 | 0.8574 | MirTarget | -0.15 | 0.00012 | NA | |
123 | hsa-miR-145-5p | MMP1 | 1.48 | 0 | -1.71 | 1.0E-5 | miRNAWalker2 validate | -0.21 | 0.03278 | NA | |
124 | hsa-miR-93-3p | MOCS1 | -0.4 | 0.00131 | 0.56 | 3.0E-5 | miRNATAP | -0.22 | 2.0E-5 | NA | |
125 | hsa-miR-93-3p | MON1B | -0.4 | 0.00131 | 0.09 | 0.25534 | miRNAWalker2 validate | -0.12 | 0.00023 | NA | |
126 | hsa-miR-93-3p | MPP5 | -0.4 | 0.00131 | 0.29 | 0.00156 | miRNAWalker2 validate | -0.1 | 0.00467 | NA | |
127 | hsa-miR-93-3p | MPPED2 | -0.4 | 0.00131 | -0.66 | 0.01633 | mirMAP | -0.3 | 0.00471 | NA | |
128 | hsa-miR-93-3p | MTUS2 | -0.4 | 0.00131 | 3.88 | 0 | miRNATAP | -0.4 | 0.01215 | NA | |
129 | hsa-miR-93-3p | N4BP2L1 | -0.4 | 0.00131 | 1.71 | 0 | MirTarget | -0.3 | 0 | NA | |
130 | hsa-miR-93-3p | NCOA1 | -0.4 | 0.00131 | 0.41 | 0 | MirTarget; miRNATAP | -0.13 | 4.0E-5 | NA | |
131 | hsa-miR-93-3p | NCOA4 | -0.4 | 0.00131 | 0.7 | 0 | miRNAWalker2 validate | -0.18 | 3.0E-5 | NA | |
132 | hsa-miR-145-5p | NEDD4L | 1.48 | 0 | -0.86 | 0 | miRNATAP | -0.23 | 0 | NA | |
133 | hsa-miR-93-3p | NFAM1 | -0.4 | 0.00131 | 1.51 | 0 | mirMAP | -0.16 | 0.04236 | NA | |
134 | hsa-miR-93-3p | NFASC | -0.4 | 0.00131 | 0.52 | 0.01556 | MirTarget; miRNATAP | -0.37 | 1.0E-5 | NA | |
135 | hsa-miR-93-3p | NFIA | -0.4 | 0.00131 | 0.92 | 0 | miRNATAP | -0.25 | 0 | NA | |
136 | hsa-miR-93-3p | NFIC | -0.4 | 0.00131 | 0.58 | 0.00749 | mirMAP | -0.33 | 0.0001 | NA | |
137 | hsa-miR-425-3p | NFIX | 0.16 | 0.22372 | 0.05 | 0.70706 | mirMAP | -0.37 | 0 | NA | |
138 | hsa-miR-93-3p | NIT1 | -0.4 | 0.00131 | 0.03 | 0.79148 | miRNATAP | -0.14 | 0.00019 | NA | |
139 | hsa-miR-93-3p | NLGN4X | -0.4 | 0.00131 | 1.28 | 0.0004 | MirTarget; miRNATAP | -0.31 | 0.03018 | NA | |
140 | hsa-miR-93-3p | NPTXR | -0.4 | 0.00131 | 0.56 | 0.09745 | mirMAP | -0.33 | 0.01107 | NA | |
141 | hsa-miR-145-5p | NRAS | 1.48 | 0 | -0.3 | 0.00029 | miRNAWalker2 validate; MirTarget; miRNATAP | -0.12 | 0 | 26973415 | miR-145 expression was significantly downregulated in colon cancer tissues with its expression in normal colonic tissues being 4-5-fold higher two sample t test P < 0.05 whereas N-ras expression showed the opposite trend |
142 | hsa-miR-145-5p | NUDT1 | 1.48 | 0 | -1.55 | 0 | miRTarBase | -0.23 | 0 | 21289483 | MiR 145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1; The mRNA expressions of EGFR and NUDT1 were significantly downregulated after miR-145 transfection in human lung adenocarcinoma cells; Our results demonstrated miR-145 in the negative regulation of EGFR and NUDT1 expressions at both mRNA and protein levels; Upregulation of miR-145 appeared to be an important gene regulation mechanism for the proliferation of lung adenocarcinoma cells and it correlated strongly with the downregulation of EGFR and NUDT1; Our findings provided new insight into the complex regulating pathway comprising of miR-145 EGFR NUDT1 and other unknown factors which function in cell proliferation but not in apoptosis |
143 | hsa-miR-93-3p | OCIAD1 | -0.4 | 0.00131 | 0.36 | 0 | miRNATAP | -0.12 | 3.0E-5 | NA | |
144 | hsa-miR-145-5p | ONECUT2 | 1.48 | 0 | -0.12 | 0.55138 | mirMAP; miRNATAP | -0.25 | 0 | NA | |
145 | hsa-miR-93-3p | PAFAH1B1 | -0.4 | 0.00131 | 0.43 | 0 | MirTarget; miRNATAP | -0.16 | 0 | NA | |
146 | hsa-miR-145-5p | PAK4 | 1.48 | 0 | -0.33 | 0.00055 | miRNAWalker2 validate; miRTarBase | -0.12 | 0 | 23499891 | We further demonstrated that miR-145 directly targeted catenin δ-1 contributing to the aberrant translocation of β-catenin through impaired nuclear shuttling with p21-activated kinase 4 PAK4 |
147 | hsa-miR-93-3p | PAMR1 | -0.4 | 0.00131 | 2.87 | 0 | miRNAWalker2 validate | -0.42 | 1.0E-5 | NA | |
148 | hsa-miR-145-5p | PAN2 | 1.48 | 0 | 0.12 | 0.24513 | MirTarget; miRNATAP | -0.12 | 1.0E-5 | NA | |
149 | hsa-miR-145-5p | PAQR9 | 1.48 | 0 | -0.14 | 0.51216 | MirTarget | -0.2 | 0.00016 | NA | |
150 | hsa-miR-93-3p | PDLIM2 | -0.4 | 0.00131 | 0.9 | 0 | mirMAP | -0.19 | 0.00019 | NA |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|
Num | Pathway | Pathview | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|---|
1 | hsa04360_Axon_guidance | 7 | 130 | 0.0008788 | 0.1257 | |
2 | hsa04720_Long.term_potentiation | 5 | 70 | 0.001396 | 0.1257 | |
3 | hsa04010_MAPK_signaling_pathway | 9 | 268 | 0.004563 | 0.2738 | |
4 | hsa00250_Alanine._aspartate_and_glutamate_metabolism | 3 | 32 | 0.006179 | 0.278 | |
5 | hsa04660_T_cell_receptor_signaling_pathway | 5 | 108 | 0.008989 | 0.3236 | |
6 | hsa04960_Aldosterone.regulated_sodium_reabsorption | 3 | 42 | 0.01313 | 0.3938 | |
7 | hsa00360_Phenylalanine_metabolism | 2 | 17 | 0.01665 | 0.4281 | |
8 | hsa04012_ErbB_signaling_pathway | 4 | 87 | 0.01937 | 0.4358 | |
9 | hsa00330_Arginine_and_proline_metabolism | 3 | 54 | 0.0256 | 0.5121 | |
10 | hsa00910_Nitrogen_metabolism | 2 | 23 | 0.02958 | 0.5324 | |
11 | hsa04390_Hippo_signaling_pathway | 5 | 154 | 0.03554 | 0.5816 | |
12 | hsa04920_Adipocytokine_signaling_pathway | 3 | 68 | 0.04596 | 0.6005 | |
13 | hsa00020_Citrate_cycle_.TCA_cycle. | 2 | 30 | 0.04821 | 0.6005 | |
14 | hsa04151_PI3K_AKT_signaling_pathway | 8 | 351 | 0.05613 | 0.6005 | |
15 | hsa04014_Ras_signaling_pathway | 6 | 236 | 0.06053 | 0.6005 | |
16 | hsa04380_Osteoclast_differentiation | 4 | 128 | 0.06442 | 0.6005 | |
17 | hsa04664_Fc_epsilon_RI_signaling_pathway | 3 | 79 | 0.06614 | 0.6005 | |
18 | hsa00270_Cysteine_and_methionine_metabolism | 2 | 36 | 0.06672 | 0.6005 | |
19 | hsa04650_Natural_killer_cell_mediated_cytotoxicity | 4 | 136 | 0.07673 | 0.626 | |
20 | hsa04910_Insulin_signaling_pathway | 4 | 138 | 0.07998 | 0.626 | |
21 | hsa00350_Tyrosine_metabolism | 2 | 41 | 0.08364 | 0.6273 | |
22 | hsa00510_N.Glycan_biosynthesis | 2 | 49 | 0.113 | 0.721 | |
23 | hsa04912_GnRH_signaling_pathway | 3 | 101 | 0.1162 | 0.721 | |
24 | hsa04916_Melanogenesis | 3 | 101 | 0.1162 | 0.721 | |
25 | hsa04150_mTOR_signaling_pathway | 2 | 52 | 0.1246 | 0.7476 | |
26 | hsa04141_Protein_processing_in_endoplasmic_reticulum | 4 | 168 | 0.1363 | 0.7917 | |
27 | hsa00590_Arachidonic_acid_metabolism | 2 | 59 | 0.1527 | 0.8327 | |
28 | hsa04722_Neurotrophin_signaling_pathway | 3 | 127 | 0.188 | 0.8728 | |
29 | hsa04115_p53_signaling_pathway | 2 | 69 | 0.1945 | 0.8728 | |
30 | hsa03320_PPAR_signaling_pathway | 2 | 70 | 0.1988 | 0.8728 | |
31 | hsa04730_Long.term_depression | 2 | 70 | 0.1988 | 0.8728 | |
32 | hsa04530_Tight_junction | 3 | 133 | 0.206 | 0.8796 | |
33 | hsa04662_B_cell_receptor_signaling_pathway | 2 | 75 | 0.2203 | 0.8796 | |
34 | hsa04370_VEGF_signaling_pathway | 2 | 76 | 0.2246 | 0.8796 | |
35 | hsa04260_Cardiac_muscle_contraction | 2 | 77 | 0.229 | 0.8796 | |
36 | hsa04146_Peroxisome | 2 | 79 | 0.2376 | 0.8796 | |
37 | hsa00564_Glycerophospholipid_metabolism | 2 | 80 | 0.242 | 0.8796 | |
38 | hsa04810_Regulation_of_actin_cytoskeleton | 4 | 214 | 0.2443 | 0.8796 | |
39 | hsa04350_TGF.beta_signaling_pathway | 2 | 85 | 0.2638 | 0.913 | |
40 | hsa04630_Jak.STAT_signaling_pathway | 3 | 155 | 0.2746 | 0.9153 | |
41 | hsa04020_Calcium_signaling_pathway | 3 | 177 | 0.3451 | 1 | |
42 | hsa04062_Chemokine_signaling_pathway | 3 | 189 | 0.3835 | 1 | |
43 | hsa04114_Oocyte_meiosis | 2 | 114 | 0.3881 | 1 | |
44 | hsa04270_Vascular_smooth_muscle_contraction | 2 | 116 | 0.3964 | 1 | |
45 | hsa04144_Endocytosis | 3 | 203 | 0.4275 | 1 | |
46 | hsa04514_Cell_adhesion_molecules_.CAMs. | 2 | 136 | 0.4762 | 1 | |
47 | hsa04120_Ubiquitin_mediated_proteolysis | 2 | 139 | 0.4876 | 1 | |
48 | hsa03013_RNA_transport | 2 | 152 | 0.5353 | 1 | |
49 | hsa04510_Focal_adhesion | 2 | 200 | 0.6838 | 1 |